Do analysts recommend GDTC or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, GDTC or GLMD?

CytoMed Therapeutics has higher revenue and earnings than Galmed Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CytoMed Therapeutics $250K 49.97 -$3.10M N/A N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A

Is GDTC or GLMD more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CytoMed Therapeutics N/A N/A N/A Galmed Pharmaceuticals N/A -29.43% -26.00%

Does the media favor GDTC or GLMD?

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.91 beat Galmed Pharmaceuticals' score of 0.23 indicating that CytoMed Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galmed Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BIVI or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BIVI or GLMD?

BioVie is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A

Is BIVI or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -29.43% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Galmed Pharmaceuticals N/A -29.43% -26.00%

Do analysts recommend COCP or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is COCP or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -29.43% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Galmed Pharmaceuticals N/A -29.43% -26.00%

Does the media refer more to COCP or GLMD?

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Cocrystal Pharma. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 1 mentions for Cocrystal Pharma. Galmed Pharmaceuticals' average media sentiment score of 0.23 beat Cocrystal Pharma's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galmed Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GLMD or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, GLMD or GELS?

Gelteq has higher revenue and earnings than Galmed Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A Gelteq $110K 68.35 -$4.30M N/A N/A

Is GLMD or GELS more profitable?

Gelteq's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -29.43% -26.00% Gelteq N/A N/A N/A

Do analysts prefer CMMB or GLMD?

Chemomab Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 1,554.53%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Chemomab Therapeutics is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CMMB or GLMD?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A

Is CMMB or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -29.43% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% Galmed Pharmaceuticals N/A -29.43% -26.00%

Galmed Pharmaceuticals (GLMD) Competitors

$0.56 -0.01 (-2.45%)

As of 10:32 AM Eastern

Compare

GLMD vs. GDTC, BIVI, COCP, GELS, and CMMB

Should you buy Galmed Pharmaceuticals stock or one of its competitors? MarketBeat compares Galmed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galmed Pharmaceuticals include CytoMed Therapeutics (GDTC), BioVie (BIVI), Cocrystal Pharma (COCP), Gelteq (GELS), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

How does Galmed Pharmaceuticals compare to CytoMed Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

CytoMed Therapeutics has higher revenue and earnings than Galmed Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	49.97	-$3.10M	N/A	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.91 beat Galmed Pharmaceuticals' score of 0.23 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galmed Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytoMed Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%

Summary

CytoMed Therapeutics beats Galmed Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to BioVie?

BioVie (NASDAQ:BIVI) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

BioVie is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

In the previous week, Galmed Pharmaceuticals had 4 more articles in the media than BioVie. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 0 mentions for BioVie. Galmed Pharmaceuticals' average media sentiment score of 0.23 beat BioVie's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
BioVie	Neutral
Galmed Pharmaceuticals	Neutral

4.6% of BioVie shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galmed Pharmaceuticals' return on equity of -29.43% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%

BioVie has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Summary

Galmed Pharmaceuticals beats BioVie on 10 of the 10 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Cocrystal Pharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Cocrystal Pharma has higher revenue and earnings than Galmed Pharmaceuticals. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	$225K	64.95	-$8.83M	-$0.73	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Cocrystal Pharma. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 1 mentions for Cocrystal Pharma. Galmed Pharmaceuticals' average media sentiment score of 0.23 beat Cocrystal Pharma's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galmed Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Galmed Pharmaceuticals' return on equity of -29.43% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%

Summary

Galmed Pharmaceuticals beats Cocrystal Pharma on 6 of the 11 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Gelteq?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Gelteq has higher revenue and earnings than Galmed Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Gelteq	$110K	68.35	-$4.30M	N/A	N/A

In the previous week, Galmed Pharmaceuticals had 4 more articles in the media than Gelteq. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 0 mentions for Gelteq. Gelteq's average media sentiment score of 1.90 beat Galmed Pharmaceuticals' score of 0.23 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Neutral
Gelteq	Very Positive

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gelteq's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
Gelteq	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galmed Pharmaceuticals has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market.

Summary

Gelteq beats Galmed Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Chemomab Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Galmed Pharmaceuticals' return on equity of -29.43% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%

Chemomab Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 1,554.53%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Chemomab Therapeutics is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galmed Pharmaceuticals had 4 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 0 mentions for Chemomab Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.23 beat Chemomab Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
Galmed Pharmaceuticals	Neutral

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

Summary

Galmed Pharmaceuticals beats Chemomab Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLMD vs. The Competition

Export

Metric	Galmed Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.06M	$3.01B	$6.58B	$12.14B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-0.45	18.64	24.81	24.06
Price / Sales	N/A	482.11	552.47	123.81
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	0.19	4.18	10.77	6.51
Net Income	-$10.31M	$64.45M	$3.56B	$337.03M
7 Day Performance	-7.03%	2.73%	1.97%	0.10%
1 Month Performance	-3.81%	2.33%	1.45%	1.07%
1 Year Performance	-69.84%	25.36%	31.07%	28.66%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLMD Galmed Pharmaceuticals	1.4434 of 5 stars	$0.56 -2.4%	N/A	-67.3%	$3.06M	N/A	N/A	20	Gap Down
GDTC CytoMed Therapeutics	1.1415 of 5 stars	$1.11 -0.1%	N/A	-51.9%	$13.11M	$324.39K	N/A	N/A	News Coverage Positive News Gap Up
BIVI BioVie	0.3615 of 5 stars	$1.74 -2.2%	N/A	-80.8%	$13.08M	N/A	N/A	10	Gap Down
COCP Cocrystal Pharma	0.6911 of 5 stars	$0.96 +1.7%	$6.00 +523.7%	-32.5%	$13.05M	N/A	N/A	10	Positive News Gap Up
GELS Gelteq	1.5152 of 5 stars	$1.21 -1.4%	N/A	-53.4%	$12.96M	$165.65K	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLMD) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. GDTC, BIVI, COCP, GELS, and CMMB

How does Galmed Pharmaceuticals compare to CytoMed Therapeutics?

Summary

How does Galmed Pharmaceuticals compare to BioVie?

Summary

How does Galmed Pharmaceuticals compare to Cocrystal Pharma?

Summary

How does Galmed Pharmaceuticals compare to Gelteq?

Summary

How does Galmed Pharmaceuticals compare to Chemomab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. GDTC, BIVI, COCP, GELS, and CMMB

How does Galmed Pharmaceuticals compare to CytoMed Therapeutics?

Which has higher valuation & earnings, GDTC or GLMD?

Do analysts recommend GDTC or GLMD?

Which has more risk & volatility, GDTC or GLMD?

Do insiders & institutionals believe in GDTC or GLMD?

Does the media favor GDTC or GLMD?

Is GDTC or GLMD more profitable?

Summary

How does Galmed Pharmaceuticals compare to BioVie?

Which has higher earnings & valuation, BIVI or GLMD?

Does the media refer more to BIVI or GLMD?

Do institutionals and insiders believe in BIVI or GLMD?

Do analysts prefer BIVI or GLMD?

Is BIVI or GLMD more profitable?

Which has more risk & volatility, BIVI or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Cocrystal Pharma?

Which has more volatility & risk, COCP or GLMD?

Which has preferable valuation & earnings, COCP or GLMD?

Do analysts recommend COCP or GLMD?

Does the media refer more to COCP or GLMD?

Do insiders & institutionals have more ownership in COCP or GLMD?

Is COCP or GLMD more profitable?

Summary

How does Galmed Pharmaceuticals compare to Gelteq?

Which has higher valuation and earnings, GLMD or GELS?

Does the media prefer GLMD or GELS?

Do insiders & institutionals believe in GLMD or GELS?

Is GLMD or GELS more profitable?

Do analysts rate GLMD or GELS?

Which has more volatility and risk, GLMD or GELS?

Summary

How does Galmed Pharmaceuticals compare to Chemomab Therapeutics?

Do insiders and institutionals hold more shares of CMMB or GLMD?

Which has more risk and volatility, CMMB or GLMD?

Is CMMB or GLMD more profitable?

Do analysts prefer CMMB or GLMD?

Does the media favor CMMB or GLMD?

Which has stronger earnings and valuation, CMMB or GLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools